Hoth Therapeutics, Inc. (HOTH): Price and Financial Metrics


Hoth Therapeutics, Inc. (HOTH): $0.42

0.00 (-1.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

HOTH Stock Price Chart Interactive Chart >

Price chart for HOTH

HOTH Price/Volume Stats

Current price $0.42 52-week high $1.75
Prev. close $0.42 52-week low $0.38
Day low $0.40 Volume 259,300
Day high $0.43 Avg. volume 4,751,209
50-day MA $0.46 Dividend yield N/A
200-day MA $0.74 Market Cap 13.37M

Hoth Therapeutics, Inc. (HOTH) Company Bio


Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.


HOTH Latest News Stream


Event/Time News Detail
Loading, please wait...

HOTH Latest Social Stream


Loading social stream, please wait...

View Full HOTH Social Stream

Latest HOTH News From Around the Web

Below are the latest news stories about Hoth Therapeutics Inc that investors may wish to consider to help them evaluate HOTH as an investment opportunity.

Hoth Therapeutics Announces the selection of NUVISAN for Manufacturing HT-001 Drug Batches for CLEER-001 Clinical Study for Cancer Patients

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with NUVISAN, a European CRO/CDMO with topical manufacturing capabilities in Sophia-Antipolis, France, to manufacture clinical batches of HT-001 topical drug product for its upcoming CLEER-001 clinical trial for cancer patients. HT-001 is a novel topical therapy in development for treatment of cutaneous toxicities associated with Epidermal Growth Factor Receptor (EGFR)

Yahoo | February 9, 2022

Hoth Therapeutics Announces Presentation of the HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data at the 2022 Alzheimer's Association International Conference

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced an abstract submission to present the preclinical Alzheimer's disease mouse model data of HT-ALZ at the Alzheimer's Association International Conference taking place July 31 – August 4, 2022 in San Diego, California.

Yahoo | February 7, 2022

Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board.

Yahoo | January 31, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, trader!

William White on InvestorPlace | January 5, 2022

Hoth Therapeutics pares gains following Alzheimer''s data; shares down 20%

No summary available.

Seeking Alpha | January 5, 2022

Read More 'HOTH' Stories Here

HOTH Price Returns

1-mo -5.19%
3-mo -39.15%
6-mo -40.39%
1-year -72.73%
3-year -92.75%
5-year N/A
YTD -36.35%
2021 -72.16%
2020 -61.71%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6543 seconds.